BMJ1d
Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
Correspondence to Professor Annette van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; A.H.M.van_der_Helm{at}lumc.nl Rheumatoid arthritis (RA) is ...
BMJ2d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ3d
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...
BMJ3d
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into ...
BMJ4d
AB0053 BERGENIN, ACTING AS AN AGONIST OF SIRT1, REDUCE SERUM URATE IN MICE THROUGH THE UPREGULATION OF ABCG2
Background: About 20% of individuals in the USA have asymptomatic hyperuricaemia [1]. However, Urate-lowering therapy in asymptomatic hyperuricaemia condition is still controversial considering the ...
BMJ5d
AB0072 PROPHYLACTIC EFFICACY OF TIXAGEVIMAB-CILGAVIMAB IN RITUXIMAB-TREATED PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES
Background: Individuals with autoimmune rheumatic diseases (ARDs) that are receiving treatment with rituximab (RTX) are at higher risk of severe outcomes upon infection with SARS-CoV-2 [1,2]. However, ...
BMJ5d
It is time to rethink juvenile idiopathic arthritis classification and nomenclature
Correspondence to Alberto Martini, University of Genoa, Pediatria II, Istituto G Gaslini, Largo Gaslini 5, Genova 16147, Italy; albertomartini{at}ospedale-gaslini.ge.it Juvenile idiopathic arthritis ...
BMJ5d
P014 FAM167A/BLK is a susceptibility locus in autoimmune diseases: characterisation of the FAM167 gene family
Introduction Genome-wide association studies of multiple autoimmune diseases, including Sjögren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis have identified associations in the ...
BMJ6d
Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein
2 Department of Orthopaedic Surgery (RKU), University of Ulm, Germany 3 Department of Internal Medicine II—Cardiology, University of Ulm, Germany Correspondence to: Dr T Stürmer Department of ...
BMJ6d
Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study
Objective To compare the treatment efficacy and safety of tofacitinib (TOF) versus methotrexate (MTX) in Takayasu arteritis (TAK). Methods Fifty-three patients with active disease from an ongoing ...
BMJ6d
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis
Objectives Nerve growth factor (NGF) has emerged as a key driver of pain in osteoarthritis (OA) and antibodies to NGF are potent analgesics in human disease. Here, we validate a novel vaccine strategy ...
BMJ7d
Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE
Objectives The goals of these studies were to elucidate the inter-relationships of specific anti-nuclear antibody (ANA), complement, and the interferon gene signature (IGS) in the pathogenesis of ...